Kala Pharmaceuticals ( (KALA) ) has released its Q1 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Kala Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for rare and severe ocular diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform.
In its first quarter of 2025 financial report, Kala Pharmaceuticals highlighted ongoing patient enrollment in the Phase 2b CHASE trial of its lead product candidate, KPI-012, for treating Persistent Corneal Epithelial Defect (PCED). The company anticipates reporting topline data in the third quarter of 2025.
The company reported a cash position of $42.2 million as of March 31, 2025, which is expected to fund operations into the first quarter of 2026. Financial results for the quarter showed a net loss of $8.9 million, an improvement from the $11.8 million loss in the same period last year. General and administrative expenses decreased to $4.6 million, while research and development expenses were slightly down to $6.1 million.
Kala Pharmaceuticals is also exploring the potential of KPI-012 for other rare eye diseases, such as Limbal Stem Cell Deficiency, and is conducting preclinical studies for inherited retinal degenerative diseases. The company remains focused on advancing KPI-012 through clinical trials, with the potential for it to serve as a pivotal trial for FDA approval.
Looking ahead, Kala Pharmaceuticals is poised to continue its development efforts with KPI-012 and its MSC-S platform, aiming to unlock new treatment options for rare ocular diseases, driven by upcoming clinical trial results and strategic advancements.